INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

InMed Pharmaceuticals ( ($INM) ) has provided an announcement. InMed Pharmaceuticals Inc. announced the selection of an intravitreal formulation ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

AMD progresses through several stages, usually starting with dry AMD, which is the more common form of the condition. It advances to geographic atrophy (GA) in some cases. Both conditions damage ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a ...

VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

The trial found that LumiThera’s Valeda Light Delivery System significantly reduced the risk of vision loss and the start of geographic atrophy in dry AMD. More than 58% of the people studied ...

The charity has described the UK medicine regulator’s decision not to approve Syfovre as “undoubtedly disappointing news” ...